Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer
The standard treatment approach for ER+ breast cancer includes surgery, radiation, or both, along with chemotherapy, endocrine therapy, targeted therapy, or combinations of these approaches. Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. The major side effect is hematologic toxicity, however, this differs from the hematologic effects associated with conventional cytotoxic chemotherapy. This educational program will provide advanced practitioners valuable insight into the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.
Posted: January 17, 2017 / Expires: January 17, 2018
Credits/Contact Hours: 1.0
Access the Activity for CE Credit*
Watch Video Without Claiming Credit